What is it about?
Hospitalized COVID-19 patients are at risk of dangerous blood clots. Doctors often use a blood test called D-dimer to assess this risk, but it’s not always reliable. Our study found that another marker, soluble thrombomodulin (sTM), can help improve predictions. When used together, sTM and D-dimer offer a better way to identify patients at high risk, helping doctors make earlier and more accurate treatment decisions.
Featured Image
Photo by Hush Naidoo Jade Photography on Unsplash
Why is it important?
Better prediction of blood clots in COVID-19 could save lives. Our study shows that adding sTM to standard tests improves risk assessment, helping doctors act earlier to prevent serious complications.
Perspectives
As a clinician, I saw firsthand how difficult it was to predict which patients would develop blood clots. Being able to contribute evidence that could improve care and prevention strategies was both a challenge and a privilege.
Sergio Padilla
Universidad Miguel Hernandez de Elche
Read the Original
This page is a summary of: Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin, PLOS One, March 2025, PLOS,
DOI: 10.1371/journal.pone.0319666.
You can read the full text:
Contributors
The following have contributed to this page
